Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Terray Therapeutics
Combines ultra high throughput chemical synthesis with AI to find small molecules.
What they do
Terray Therapeutics integrates massive physical chemical experimentation with generative artificial intelligence. Their proprietary platform generates vast biochemical datasets to design and optimize novel small molecule therapeutics for hard to target diseases.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Pasadena, United States
- Region
- North America
- Founded
- 2018
- Total funding
- $200M raised
Notable investors: Madrona, Two Sigma Ventures, F-Prime Capital, Goldman Sachs Asset Management.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA